It is not often that clinical trials assess the treatment convenience of a therapy by testing the advantages of one particular mode of administration over another for patients with cancer. At the recent ASCO Genitourinary Cancers Symposium, results of a randomized, open-label, phase III trial (CheckMate 67T) reported that subcutaneous nivolumab was non-inferior to intravenous nivolumab on the basis of two co-primary pharmacokinetic endpoints and overall response rate. Importantly, the average time to administer nivolumab subcutaneously is 5 minutes, compared with 30 minutes for intravenous therapy. Dr Saby George, lead author of the study notes stated, “subcutaneous nivolumab is a new standard for clear-cell renal cell carcinoma that will decrease treatment burden and improve health-care efficacy.” Access to care could be improved with this mode of treatment as it can be delivered in a clinic rather than an infusion centre. This finding provides welcome news to patients and simultaneously maximises efficiencies within health-care systems. “By freeing up infusion chairs, more patients can get access to the medicines they need more quickly,” Dr George highlights.
- Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
- Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer
- Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
- Amtagvi – first cellular therapy approval for unresectable melanoma
- NEVER under-estimate the clinical and commercial value of a chemotherapy backbone to your blockbuster drug – even Tagrisso benefitted from this rocket fuel!